Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Do Financial Conflicts Impact Pathway Development?
JAMA Oncol.; ePub 2017 Dec 21; Daly, Bach, et al
Financial conflicts of interest appear to have an impact on clinical pathway development, researchers concluded after conducting a recent analysis. Investigators used the CMS open payments database to assess 2015 financial conflicts of interest for 1) 2016 voting members of NCCN’s Value Pathways (which represents McKesson Specialty Health, US Oncology, and NCCN); 2) the medical oncology committee chairs for Via Oncology; and 3) the medical advisory board for eviti. The vast majority of physicians received non-research payments (92% of US Oncology voting members; 86% of NCCN voting members; 84% of Via Oncology chairs; and 69% of the eviti medical advisory board). $10,000 or more in general payments was received by:
- 15% of the US Oncology board.
- 19% of the eviti medical advisory board.
- 28% of Via Oncology chairs.
- 47% of the NCCN voting members.
The authors noted that the 5 vendors analyzed represent >60% of the oncology clinical pathway market share.
Daly B, Bach P, Page R. Financial conflicts of interest among oncology clinical pathway vendors. [Published online ahead of print December 21, 2017]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4473.